Novartis skin cancer drug shrinks tumors in Phase II trial
ZURICH (Reuters) - An experimental drug from Novartis markedly shrank tumors in patients with advanced basal cell carcinoma, the most common form of skin cancer, according to the results of a mid-stage study published on Sunday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Basal Cell Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Health | Skin | Skin Cancer | Study